共 50 条
- [1] Investigating Efficacy, Safety, and Biomarkers in a Phase 2 Trial of Pomalidomide plus Low-Dose Dexamethasone (POM plus LoDEX) Following Second-Line Lenalidomide-Based Therapy (Tx) in Relapsed or Refractory Multiple Myeloma (RRMM)BLOOD, 2015, 126 (23)Siegel, David S.Schiller, GarySong, KevinAgajanian, RichyStockerl-Goldstein, KeithKaya, HakanSebag, MichaelReu, Frederic J.Mouro, JorgeSturniolo, MichaelSrinivasan, ShankarThakurta, AnjanNagarwala, YasirBahlis, Nizar J.
- [2] Pomalidomide Plus Low-Dose Dexamethasone (POM plus LoDEX) for Relapsed and Refractory Multiple Myeloma (RRMM): Results from a Pharmacoeconomic EvaluationBLOOD, 2014, 124 (21)Schey, SteveDhanasiri, SujithLee, DawnSternas, LarsYu, XinZaki, Mohamed H.Elvidge, JamieO'Dwyer, Michael
- [3] Phase 2 Study of Pomalidomide (POM) plus Low-Dose Dexamethasone (LoDEX) Following Second-Line Lenalidomide (LEN)-Based Treatment (Tx) in Patients (Pts) With Relapsed or Refractory Multiple Myeloma (RRMM): An Updated Analysis of Efficacy and SafetyCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E141 - E141Siegel, David S.Schiller, Gary J.Song, KevinAgajanian, RichyStockerl-Goldstein, KeithKaya, HakanSebag, MichaelReu, Frederic J.Malek, EshanMouro, JorgeChung, WeiyuanSrinivasan, ShankarQian, MaxRizvi, SyedThakurta, AnjanBahlis, Nizar J.
- [4] Pomalidomide (POM) plus low-dose dexamethasone (LoDEX) plus daratumumab (DARA) in relapsed and/or refractory multiple myeloma (RRMM) after lenalidomide (LEN)-based treatment (Tx) failure.JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)Siegel, David Samuel DiCapuaSchiller, Gary J.Samaras, Christy JoySebag, MichaelBerdeja, Jesus G.Ganguly, SiddharthaMatous, JeffreySong, Kevin W.Seet, ChristopherTalamo, GiampaoloSrinivas, ShanthiAcosta-Rivera, MirelisBar, MichaelQuick, DonaldAnz, Bertrand MarquessFonseca, GustavoReece, Donna EllenZafar, FaizaChung, WeiyuanBahlis, Nizar J.
- [5] Immune Profile of Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM) Treated with Pomalidomide (POM) plus Low-Dose Dexamethasone (LoDEX) plus Daratumumab (DARA) in the Second Line Immediately after Lenalidomide (LEN)BLOOD, 2017, 130Qian, XiaozhongNewhall, KathrynTometsko, MarkBjorklund, ChadMa, JianglinBahlis, Nizar J.Siegel, DavidSchiller, Gary J.Samaras, ChristySebag, MichaelBerdeja, Jesus G.Ganguly, SiddharthaMatous, Jeffrey V.Song, Kevin W.Seet, Christopher S.Talamo, GiampaoloSrinivas, ShanthiAcosta-Rivera, MirelisBar, MichaelQuick, DonaldAnz, BertrandFonseca, GustavoReece, DonnaMouro, JorgeAgarwal, AmitZafar, FaizaThakurta, Anjan
- [6] Safety and Efficacy of Pomalidomide Plus Low-Dose Dexamethasone (POM plus LoDEX) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) in Italy: A Subanalysis of the Stratus Trial (MM-010)BLOOD, 2015, 126 (23)Cavo, MicheleCorradini, PaoloDi Raimondo, FrancescoPetrini, MarioCafro, Anna Mariadi Toritto, Tommaso CaravitaOffidani, MassimoSemenzato, GianpietroZambello, RenatoLazzaro, AntonioPetrucci, Maria TeresaRodeghiero, FrancescoSimcock, MathewSlaughter, AnaHerring, JenniferPeluso, TeresaPalumbo, Antonio
- [7] An Updated Analysis of the Stratus Trial (MM-010): Safety and Efficacy of Pomalidomide Plus Low-Dose Dexamethasone (POM plus LoDEX) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)BLOOD, 2015, 126 (23)Dimopoulos, Meletios A.Palumbo, AntonioCorradini, PaoloCavo, MicheleDelforge, MichelWeisel, Katja C.Ocio, Enrique M.Di Raimondo, FrancescoHansson, MarkusSimcock, MathewMiller, NeilSlaughter, AnaPeluso, TeresaSternas, LarsZaki, Mohamed H.Moreau, Philippe
- [8] Pomalidomide plus low-dose dexamethasone (POM plus LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM): Impact of cytogenetics in MM-003JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)Goldschmidt, HartmutDimopoulos, Meletios A.Weisel, Katja C.Moreau, PhilippeLacy, MarthaSong, Kevin W.Delforge, MichelKarlin, LionelBanos, AnneRocafiguera, Albert OriolYu, XinSternas, LarsJacques, ChristianZaki, Mohamed H.San-Miguel, Jesus F.
- [9] POMALIDOMIDE (POM) plus LOW-DOSE DEXAMETHASONE (LODEX) AFTER SECOND-LINE LENALIDOMIDE (LEN)-BASED TREATMENT OF RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED PROGRESSION-FREE SURVIVAL ANALYSISHAEMATOLOGICA, 2017, 102 : 511 - 511Siegel, D. S.Schiller, G. J.Song, K.Agajanian, R.Stockerl-Goldstein, K.Kaya, H.Sebag, M.Reu, F. J.Malek, E.Talamo, G.Mouro, J.Chung, W.Srinivasan, S.Qian, M.Rizvi, S.Thakurta, A.Bahlis, N. J.
- [10] Safety and Efficacy of Pomalidomide (POM) plus Low-Dose Dexamethasone (LoDEX) plus Daratumumab (DARA) As Second- or Third-Line Therapy in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM) after Lenalidomide (LEN) Based Treatment (Tx) FailureBLOOD, 2017, 130Siegel, DavidSchiller, Gary J.Samaras, ChristySebag, MichaelBerdeja, Jesus G.Ganguly, SiddharthaMatous, Jeffrey V.Song, Kevin W.Seet, Christopher S.Talamo, GiampaoloSrinivas, ShanthiAcosta-Rivera, MirelisBar, MichaelQuick, DonaldAnz, BertrandFonseca, GustavoReece, DonnaMouro, JorgeAgarwal, AmitZafar, FaizaQian, MaxThakurta, AnjanBahlis, Nizar J.